Trial Profile

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Malignant-mesothelioma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Dec 2025 According to Results presentedin the Nature Medicine, Primary endpoint (Feasibility of neoadjuvant nivolumab +/- ipilimumab in patients with resectable MPM who complete of neoadjuvant treatment and proceed to surgery) has been met.
01 Dec 2025 Results presentedin the Nature Medicine
26 Jun 2025 Planned End Date changed from 1 Jun 2026 to 1 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com